B·R·A·H·M·S Biomarkers: Software for Pre-eclampsia Screening

Prenatal software: B·R·A·H·M·S Fast Screen pre I plus for pre-eclampsia screening

Discover our modern, powerful and robust clinical prenatal screening software for pre-eclampsia in first trimester.

 

Thermo Scientific B·R·A·H·M·S Fast Screen pre I plus is a CE marked prenatal screening software. This software, designed to be used with Thermo Scientific B·R·A·H·M·S KRYPTOR Instruments and Assays, ensures convenience of data entry, risk calculation and reporting for laboratories with both low and high data throughput. 

Key features

Maximum data security and traceability

  • Software audit option for external quality control
  • Internal audits
  • Missing or out of range data warnings
  • Data validation before report production
  • Automatic saving
  • Four levels of user credentials

Effective management tools

  • Statistic and audit reports
  • Pregnancy outcome requests and follow-up information
  • Database search tool
  • Export data for statistics and research
  • Report printing one by one or in batches
  • Automatic printing, saving, and sending of reports by email
  • Can keep extended patient data for record purposes

High connectivity

  • Manual entry of patient data and connection to KRYPTOR
  • Automatic data transfer via Laboratory Information System (LIS)

Pre-eclampsia screening algorithms

B·R·A·H·M·S Fast Screen pre I plus comprises algorithms that are based on the Fetal Medicine Foundation UK (FMF) data and are updated with recently published correction factors.

  Pre-eclampsia
Time range
  • From 11+2 to 14+0 for biochemistry
  • From 45 mm to 84 mm for ultrasound
Biomarkers
  • PAPP-A
  • PlGF 
Physical markers
  • Mean arterial pressure (MAP)
  • Uterine arteries pulsatility index (UtA-PI)

The medians of the B·R·A·H·M·S biochemical markers free βhCG, PAPP-A and PlGF which are included in our software are extremely stable. These medians were established on over 220,000 healthy pregnancies which ensures reproducibility and robustness of the risk calculation.1,2 Therefore, a recalculation of the medians and MoMs over time is not required.

FMF first trimester test performances for pre-eclampsia

View the FMF pre-eclampsia algorithm performances below.3

  Early onset pre-eclampsia
(< week 32)		 Intermediate onset pre-eclampsia 
(< week 37)		 Late onset
pre-eclampsia
(≥ week 37)
Detection rate 100% 75% 43%
False positive rate 10% 10% 10%

More than just a risk calculation tool for your pre-eclampsia screening

Simple and user-friendly interface available in six languages

Available in English, German, French, Spanish, Italian, and Turkish

References

  1. Concerning free βhCG and PAPP-A medians please refer to D. Wright et al., “First-trimester combined screening for trisomy 21 at 7-14 weeks’ gestation” Ultrasound Obstet. Gynecol., vol. 36, no. 4, pp. 404–411, 2010.
  2. Concerning PlGF medians please refer to P. Pandya et al., “Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks’ gestation” Fetal Diagn. Ther., vol. 31, no. 2, pp. 87–93, 2012.
  3. N. O’Gorman et al., “Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation” Ultrasound Obstet. Gynecol., vol. 208, no. 2, pp. 109–112, Jan. 2017.

Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.

 

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.

 

KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.